Normal vascular function despite low levels of high-density lipoprotein cholesterol in carriers of the apolipoprotein A-IMilano mutant

Circulation

Volumn 116, Issue 19, 2007, Pages 2165-2172

  Gomaraschi, Monica ^a   Baldassarre, Damiano ^a,b   Amato, Mauro ^b   Eligini, Sonia ^a   Conca, Paola ^a   Sirtori, Cesare R ^a   Franceschini, Guido ^a,c   Calabresi, Laura ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b CENTRO CARDIOLOGICO MONZINO   (Italy)

^c Center E Grossi Paoletti   (Italy)

Author keywords

Apolipoproteins; Cell adhesion molecules; Lipoproteins; Nitric oxide; Vasodilation

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN B; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERCELLULAR ADHESION MOLECULE 1; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MUTANT PROTEIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ARTERY COMPLIANCE; ARTICLE; BLOOD VESSEL REACTIVITY; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; HETEROZYGOTE; HUMAN; HUMAN CELL; HYPEREMIA; LIMB ISCHEMIA; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; AGED; APOLIPOPROTEIN A-I; CELLS, CULTURED; COMPLIANCE; ENDOTHELIUM, VASCULAR; FEMALE; FOREARM; HETEROZYGOTE; HOMEOSTASIS; HUMANS; HYPEREMIA; INTERCELLULAR ADHESION MOLECULE-1; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; MUTATION; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; REGIONAL BLOOD FLOW; UMBILICAL VEINS; VASCULAR CELL ADHESION MOLECULE-1; VASODILATION;

EID: 35848948176     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.107.705657     Document Type: Article

References (37)

1. Milano apoprotein: decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family. J Clin Invest. 1980;66:892-900.
2. Milano: detection of normal AI in affected subjects and evidence for a cysteine for arginine substitution in the variant AI. J Biol Chem. 1983;258:2508-2513.
3. Milano apoprotein: identification of the complete kindred and evidence of a dominant genetic transmission. Am J Hum Genet. 1985;37:1083-1097.
4. Franceschini G, Sirtori CR, Bosisio E, Gualandri V, Orsini GB, Mogavero AM, Capurso A. Relationship of the phenotypic expression of the A-IMilano apoprotein with plasma lipid and lipoprotein patterns. Atherosclerosis. 1985;58:159-174.
5. Milano mutant: the Limone sul Garda Study. Circulation. 2001;103:1949-1954.
6. Favari E, Gomaraschi M, Zanotti I, Bernini F, Lee-Rueckert M, Kovanen PT, Sirtori CR, Franceschini G, Calabresi L. A unique protease-sensitive high density lipoprotein particle containing the apolipoprotein A-IMilano dimer effectively promotes ATP-binding cassette A1-mediated cell cholesterol efflux. J Biol Chem. 2007;282:5125-5132.
7. Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol. 2003;23:168-175.
8. Badimon JJ, Fuster V, Chesebro JH, Badimon L. Coronary atherosclerosis: a multifactorial disease. Circulation. 1993;87(suppl II):II-3-II-16.
9. Vaudo G, Marchesi S, Lupattelli G, Pirro M, Pasqualini L, Roscini AR, Siepi D, Schillaci G, Mannarino E. Early vascular damage in primary hypoalphalipoproteinemia. Metabolism. 2003;52:328-332.
10. Bisoendial RJ, Hovingh GK, Levels JH, Lerch PG, Andresen I, Hayden MR, Kastelein JJ, Stroes ES. Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein. Circulation. 2003;107:2944-2948.
11. Kuvin JT, Patel AR, Sidhu M, Rand WM, Sliney KA, Pandian NG, Karas RH. Relation between high-density lipoprotein cholesterol and peripheral vasomotor function. Am J Cardiol. 2003;92:275-279.
12. Baldassarre D, Amato M, Palombo C, Morizzo C, Pustina L, Sirtori CR. Time course of forearm arterial compliance changes during reactive hyperemia. Am J Physiol Heart Circ Physiol. 2001;281:H1093-H1103.
13. Calabresi L, Gomaraschi M, Villa B, Omoboni L, Dmitrieff C, Franceschini G. Elevated soluble cellular adhesion molecules in subjects with low HDL-cholesterol. Arterioscler Thromb Vasc Biol. 2002;22:656-661.
14. Chan NN, Colhoun HM, Vallance P. Cardiovascular risk factors as determinants of endothelium-dependent and endothelium-independent vascular reactivity in the general population. J Am Coll Cardiol. 2001;38:1814-1820.
15. Lupattelli G, Marchesi S, Roscini A, Siepi D, Gemelli F, Pirro M, Sinzinger H, Schillaci G, Mannarino E. Direct association between high-density lipoprotein cholesterol and endothelial function in hyperlipemia. Am J Cardiol. 2002;90:648-650.
16. O'Brien SF, Watts GF, Playford DA, Burke V, O'Neal DN, Best JD. Low-density lipoprotein size, high-density lipoprotein concentration, and endothelial dysfunction in non-insulin-dependent diabetes. Diabet Med. 1997;14:974-978.
17. Zhang X, Zhao SP, Li XP, Gao M, Zhou QC. Endothelium-dependent and -independent functions are impaired in patients with coronary heart disease. Atherosclerosis. 2000;149:19-24.
18. Kuvin JT, Ramet ME, Patel AR, Pandian NG, Mendelsohn ME, Karas RH. A novel mechanism for the beneficial vascular effects of high-density lipoprotein cholesterol: enhanced vasorelaxation and increased endothelial nitric oxide synthase expression. Am Heart J. 2002;144:165-172.
19. Pyke KE, Tschakovsky ME. The relationship between shear stress and flow-mediated dilatation: implications for the assessment of endothelial function. J Physiol. 2005;568:357-369.
20. Joannides R, Haefeli WE, Linder L, Richard V, Bakkali EH, Thuillez C, Luscher TF. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation. 1995;91:1314-1319.
21. Yuhanna IS, Zhu Y, Cox BE, Hahner LD, Osborne-Lawrence S, Lu P, Marcel YL, Anderson RG, Mendelsohn ME, Hobbs HH, Shaul PW. High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat Med. 2001;7:853-857.
22. Calabresi L, Gomaraschi M, Franceschini G. Endothelial protection by high-density lipoproteins: from bench to bedside. Arterioscler Thromb Vasc Biol. 2003;23:1724-1731.
23. De Caterina R, Basta G, Lazzerini G, Dell'Omo G, Petrucci R, Morale M, Carmassi F, Pedrinelli R. Soluble vascular cell adhesion molecule-1 as a biohumoral correlate of atherosclerosis. Arterioscler Thromb Vasc Biol. 1997;17:2646-2654.
24. Calabresi L, Rossoni G, Gomaraschi M, Sisto F, Berti F, Franceschini G. High-density lipoproteins protect isolated rat hearts from ischemia-reperfusion injury by reducing cardiac tumor necrosis factor-alpha content and enhancing prostaglandin release. Circ Res. 2003;92:330-337.
25. Cockerill GW, Rye KA, Gamble JR, Vadas MA, Barter PJ. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol. 1995;15:1987-1994.
26. Milano carriers and transgenic mice. Arterioscler Thromb Vasc Biol. 1999;19:1257-1262.
27. Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation. 2007;115:1285-1295.
28. Verma S, Buchanan MR, Anderson TJ. Endothelial function testing as a biomarker of vascular disease. Circulation. 2003;108:2054-2059.
29. Lupattelli G, Lombardini R, Schillaci G, Ciuffetti G, Marchesi S, Siepi D, Mannarino E. Flow-mediated vasoactivity and circulating adhesion molecules in hypertriglyceridemia: association with small, dense LDL cholesterol particles. Am Heart J. 2000;140:521-526.
30. Witte DR, Broekmans WM, Kardinaal AF, Klopping-Ketelaars IA, van PG, Bots ML, Kluft C, Princen JM. Soluble intercellular adhesion molecule 1 and flow-mediated dilatation are related to the estimated risk of coronary heart disease independently from each other. Atherosclerosis. 2003;170:147-153.
31. Kaul S, Coin B, Hedayiti A, Yano J, Cercek B, Chyu KY, Shah PK. Rapid reversal of endothelial dysfunction in hypercholesterolemic apolipoprotein E-null mice by recombinant apolipoprotein A-I(Milano)-phospholipid complex. J Am Coll Cardiol. 2004;44:1311-1319.
32. Wang L, Sharifi BG, Pan T, Song L, Yukht A, Shah PK. Bone marrow transplantation shows superior atheroprotective effects of gene therapy with apolipoprotein A-I Milano compared with wild-type apolipoprotein A-I in hyperlipidemic mice. J Am Coll Cardiol. 2006;48:1459-1468.
33. Cohen JC, Kiss RS, Pertsemlidis A, Marcel YL, McPherson R, Hobbs HH. Multiple rare alleles contribute to low plasma levels of HDL cholesterol. Science. 2004;305:869-872.
34. Hovingh GK, de Groot E, van der Steeg W, Boekholdt SM, Hutten BA, Kuivenhoven JA, Kastelein JJ. Inherited disorders of HDL metabolism and atherosclerosis. Curr Opin Lipidol. 2005;16:139-145.
35. Calabresi L, Franceschini G. High density lipoprotein and coronary heart disease: insights from mutations leading to low high density lipoprotein. Curr Opin Lipidol. 1997;8:219-224.
36. Norum RA, Lakier JB, Goldstein S, Angel A, Goldberg RB, Block WD, Nofze DK, Dolphin PJ, Edelglass J, Bogorad DD, Alaupovic P. Familial deficiency of apolipoproteins A-I and C-III and precocious coronary heart disease. N Engl J Med. 1982;306:1513-1519.
37. Hovingh GK, Brownlie A, Bisoendial RJ, Dube MP, Levels JH, Petersen W, Dullaart RP, Stroes ES, Zwinderman AH, de Groot E, Hayden MR, Kuivenhoven JA, Kastelein JJ. A novel apoA-I mutation (L178P) leads to endothelial dysfunction, increased arterial wall thickness, and premature coronary artery disease. J Am Coll Cardiol. 2004;44:1429-1435.